Almac and the Medical Research Council (MRC) have entered into a partnership to undertake a study in metastatic colorectal cancer (mCRC) using samples from the MRC COIN trial.
The aim of the study is to assess potential biomarkers of response to cetuximab (Erbitux).
Almac will utilise samples from the COIN trial to carry out quantitative polymerase chain-reaction profiling and data analysis to assess other potential biomarkers in the context of combination therapy with cetuximab.
The MRC COIN study is a phase III, multicentre, three-arm study in first-line treatment of mCRC.
The study focuses on examining whether the combination of oxaliplatin and cetuximab with fluoropyrimidine chemotherapy improves patient outcomes.
